Views

CrossRef citations to date

Altmetric

Original Research

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry

Patrick Goldstein1 Emergency Department, Lille Regional University Hospital, Lille, FranceCorrespondence[email protected]

Niccolò Grieco2 Department of Cardiology, Hospital Niguarda Cà Granda Milano, Milan, Italy

Hüseyin Ince3 Internal Medicine Centre, Cardiology Department, Rostock University Clinic, Rostock, Germany;4 Department of Cardiology, Vivantes Klinikum im Friedrichshain and Am Urban, Berlin, Germany

Nicolas Danchin5 Department of Cardiology, European Hospital Georges-Pompidou, Paris, France

Yvonne Ramos6 Medical Department, Daiichi Sankyo Europe, Munich, Germany

Jochen Goedicke7 Medical Department, Lilly Deutschland GmbH, Bad Homburg, Germany

Peter Clemmensen8 Department of Medicine, Division of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;9 Department of Medicine, Division of Cardiology, Nykoebing F Hospital, Copenhagen, Denmark

show all

Figures & data

Figure 1 Patient flow and disposition.

Notes: ^aDifferent from baseline data reported earlier, as one patient needed to be withdrawn (informed consent form was lost). ^bThirty-one missed loading dose, ten received loading dose in catheterization laboratory, one vomited after loading dose, one had no initial STEMI diagnosis. ^cIncludes ten patients who died in-hospital and 2,026 patients discharged from hospital with available 1-year follow-up information.
Abbreviations: C, clopidogrel; P, prasugrel; STEMI, ST-elevation myocardial infarction.

Table 1 Baseline characteristics, by P2Y₁₂-inhibitor treatment from loading dose through hospital discharge

Download CSV Display Table

Figure 2 Death rates from hospital admission through 1 year.

Notes: Analysis is restricted to patients with documented 1-year follow-up (n=2,036).
Abbreviations: C, clopidogrel; CV, cardiovascular; P, prasugrel.

Figure 3 CV death from hospital admission through 1 year by P2Y₁₂-inhibitor treatment.

Notes: *Switched from clopidogrel. Confidence intervals were adjusted for differences in baseline characteristics. Data are based on linear regression model.
Abbreviation: CV, cardiovascular.

Figure 3 CV death from hospital admission through 1 year by P2Y12-inhibitor treatment.

Figure 4 Patient disposition by P2Y₁₂-inhibitor prescribed at hospital discharge.

Notes: ^aThirty-one missed loading dose, ten received loading dose in catheterization laboratory, one vomited after loading dose, one had no initial STEMI diagnosis. ^bDifferent from baseline data reported earlier, as one patient needed to be withdrawn (informed consent form was lost).
Abbreviation: STEMI, ST-elevation myocardial infarction.

Figure 4 Patient disposition by P2Y12-inhibitor prescribed at hospital discharge.

Table 2 Baseline characteristics by P2Y₁₂-inhibitor treatment prescribed at hospital discharge

Download CSV Display Table

Figure 5 CV death from hospital discharge to 1-year follow-up by P2Y₁₂-inhibitor prescribed at hospital discharge.

Notes: Confidence intervals were adjusted for differences in baseline characteristics. Data are based on linear regression model.
Abbreviation: CV, cardiovascular.

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry

Table 1 Baseline characteristics, by P2Y₁₂-inhibitor treatment from loading dose through hospital discharge

Table 2 Baseline characteristics by P2Y₁₂-inhibitor treatment prescribed at hospital discharge

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry

Figures & data

Table 1 Baseline characteristics, by P2Y12-inhibitor treatment from loading dose through hospital discharge

Table 2 Baseline characteristics by P2Y12-inhibitor treatment prescribed at hospital discharge

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1 Baseline characteristics, by P2Y₁₂-inhibitor treatment from loading dose through hospital discharge

Table 2 Baseline characteristics by P2Y₁₂-inhibitor treatment prescribed at hospital discharge